Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation

The prognostic significance of detecting minimal residual disease by polymerase chain reaction (PCR) amplification of bcr/abl mRNA transcripts was investigated in 27 bone marrow samples from 20 patients with Philadelphia chromosome (Ph1) positive chronic myelogenous leukaemia (CML) in complete cytogenetic remission following allogeneic bone marrow transplantation. Sixteen were transplanted in first chronic phase, two were in second chronic phase, one was in accelerated phase and one was in blast crisis. All 20 achieved complete cytogenetic remission post transplant and 15 patients had detectable bcriabl mRNA by PCR from 2 to 22 months following the procedure. One of these patients had graft failure and one died from graft‐versus‐host‐disease at 7 months. Of the remaining 13 PCR‐positive patients, only one (8%) relapsed after 23 months: the other 12 were alive and still in remission after a median follow‐up of 16 + months (ranging 5+ to 29+ months). Five patients were PCR negative: all are alive in complete clinical and cytogenetic remission at lo +, 11 +, 19 +, 25+ and 25+ months post transplant. In this study, detection of subclinical Phl‐positive cells by PCR was not associated with imminent clinical or cytogenetic relapse. Since late recurrence may potentially occur, long‐term follow‐up is required to definitely determine the prognostic value of the PCR assay.

[1]  Emil,et al.  Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. , 1992, Blood.

[2]  J. Goldman.  Bone marrow transplantation for chronic myelogenous leukemia , 1992, Current opinion in oncology.

[3]  J. Ritz,et al.  Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. , 1991, Blood.

[4]  M. Slovak,et al.  PERSISTENCE OF bcr‐abl GENE EXPRESSION FOLLOWING BONE MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE , 1991 .

[5]  M. Slovak,et al.  Persistence of bcr-able gene expression following bone marrow transplantation for chronic myelogenous leukemia in chronic phase. , 1991, Transplantation.

[6]  G. Morgan,et al.  Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. , 1991, Blood.

[7]  J. Sosman,et al.  The graft versus leukemia effect: possible mechanisms and clinical significance to the biologic therapy of leukemia. , 1991, Bone marrow transplantation.

[8]  K. Offit,et al.  Cytogenetic analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T cell-depleted bone marrow transplantation. , 1990, Blood.

[9]  M. Vidaud,et al.  Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia. , 1990, Leukemia.

[10]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[11]  C. Sawyers,et al.  Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Gabert,et al.  DETECTION OF RESIDUAL bcr/abl TRANSLOCATION BY POLYMERASE CHAIN REACTION IN CHRONIC MYELOID LEUKAEMIA PATIENTS AFTER BONE-MARROW TRANSPLANTATION , 1989, The Lancet.

[13]  D. Ginsburg,et al.  Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia , 1989 .

[14]  S. Kwok,et al.  Avoiding false positives with PCR , 1989, Nature.

[15]  R Storb,et al.  Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. , 1989, Blood.

[16]  G. Morgan,et al.  POLYMERASE CHAIN REACTION FOR DETECTION OF RESIDUAL LEUKAEMIA , 1989, The Lancet.

[17]  E. Thomas,et al.  Indications for marrow transplantation in chronic myelogenous leukemia. , 1989, Blood.

[18]  S. Feig,et al.  Selective depletion of CD8 positive T-lymphocytes for prevention of graft-versus-host disease following allogeneic bone marrow transplantation. , 1989, Transplantation proceedings.

[19]  D. Ginsburg,et al.  Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia. , 1989, Blood.

[20]  J U Gutterman,et al.  The molecular genetics of Philadelphia chromosome-positive leukemias. , 1988, The New England journal of medicine.

[21]  H. Kantarjian,et al.  Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction. , 1988, Blood.

[22]  S. Smith,et al.  Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Goldman,et al.  Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase. , 1988, Blood.

[24]  D. Baltimore,et al.  The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia , 1987, Molecular and cellular biology.

[25]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[26]  A. Berrebi,et al.  bcr-abl RNA in patients with chronic myelogenous leukemia. , 1987, Blood.

[27]  Kees Stam,et al.  Structural organization of the bcr gene and its role in the Ph′ translocation , 1985, Nature.

[28]  O. Witte,et al.  Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Groudine,et al.  Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells. , 1984, Science.

[30]  E. Canaani,et al.  ALTERED TRANSCRIPTION OF AN ONCOGENE IN CHRONIC MYELOID LEUKAEMIA , 1984, The Lancet.

[31]  J. Stephenson,et al.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 , 1984, Cell.

[32]  J. Stephenson,et al.  Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia , 1983, Nature.

[33]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.